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Proteasome activity is required 
for the initiation of precancerous 
pancreatic lesions
Takaki Furuyama1,2, Shinji Tanaka1,2, Shu Shimada1, Yoshimitsu Akiyama1, 
Satoshi Matsumura2, Yusuke Mitsunori2, Arihiro Aihara2, Daisuke Ban2, Takanori Ochiai2, 
Atsushi Kudo2, Hiroshi Fukamachi1, Shigeki Arii2, Yoshiya Kawaguchi3 & Minoru Tanabe2
Proteasome activity is significantly increased in advanced cancers, but its role in cancer initiation is 
not clear, due to difficulties in monitoring this process in vivo. We established a line of transgenic mice 
that carried the ZsGreen-degronODC (Gdeg) proteasome reporter to monitor the proteasome activity. In 
combination with Pdx-1-Cre;LSL-KrasG12D model, proteasome activity was investigated in the initiation 
of precancerous pancreatic lesions (PanINs). Normal pancreatic acini in Gdeg mice had low proteasome 
activity. By contrast, proteasome activity was increased in the PanIN lesions that developed in 
Gdeg;Pdx-1-Cre;LSL-KrasG12D mice. Caerulein administration to Gdeg;Pdx-1-Cre;LSL-KrasG12D mice 
induced constitutive elevation of proteasome activity in pancreatic tissues and accelerated PanIN 
formation. The proteasome inhibitor markedly reduced PanIN formation in Gdeg;Pdx-1-Cre;LSL-
KrasG12D mice (P = 0.001), whereas it had no effect on PanIN lesions that had already formed. These 
observations indicated the significance of proteasome activity in the initiation of PanIN but not the 
maintenance per se. In addition, the expressions of pERK and its downstream factors including cyclin 
D1, NF-κB, and Cox2 were decreased after proteasome inhibition in PanINs. Our studies showed 
activation of proteasome is required specifically for the initiation of PanIN. The roles of proteasome in 
the early stages of pancreatic carcinogenesis warrant further investigation.
Pancreatic cancer is one of the most deadly human cancers. It is usually diagnosed at an advanced stage and is 
resistant to therapy1. Therefore, there is a dire need for new therapeutic approaches based on a better under-
standing of the biology of this disease2. Pancreatic ductal adenocarcinoma (PDAC), the most common form of 
pancreatic cancer, arises from a spectrum of preneoplastic mucinous lesions with ductal morphology, namely 
pancreatic intraepithelial neoplasias (PanINs)3. The earliest detectable mutations found in PanINs are activating 
mutations of the KRAS gene. More than 90% of cases of PanINs of all grades have KRAS mutations4. In the mouse 
model, constitutive expression of mutant KRAS in pancreatic acinar cells spontaneously induce PanINs5. PanIN 
formation is preceded by acinar-to-ductal metaplasia (ADM), a process of dedifferentiation of acinar cells to 
ductal cells6. Acute pancreatitis induces transient ADM followed by reversion to normal acinar cell morphol-
ogy in the absence of mutant KRAS7. By contrast, mutant KRAS dramatically accelerates the ADM to PanIN 
sequence8. These observations indicate the significance of KRAS mutations for the initiation of PanIN, but the 
detailed mechanisms remain unknown.
RAS mutant cancers show selective dependencies on activities that are not regulated by Ras, but that are 
needed to adapt to the stress induced by the process of transformation. This phenomenon is referred to as 
“non-oncogene addiction”9. One of the key components of such activities is the proteasome. The proteasome 
degrades short-lived regulatory proteins involved in various cellular functions. Additionally, it removes mis-
folded and damaged proteins10. In cancer cells, proteotoxic stress is a frequent occurrence resulting from exces-
sive amounts of misfolded proteins that lead to enhanced proteasome activity11. Cancer cells with mutant KRAS 
show selective addiction to proteasome activity, and proteasome inhibition shows synthetic lethality with mutant 
KRAS12,13.
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Increased protein turnover is one aspect of advanced cancers including PDAC, but a recent study suggests 
that it begins much earlier than previously appreciated and can be an early event in development of PDAC14. 
Thus, the proteasome potentially has roles in the early stages of cancer initiation. But so far, its impact on can-
cer initiation has not been elucidated. One of the reasons is the difficulty in evaluating proteasome activity in 
vivo. Dantuma et al. developed UbG76V-GFP proteasome reporter system that allows rapid quantification of 
ubiquitin-proteasome-dependent proteolysis in living cell15. They further developed a transgenic mouse model 
with this reporter for in vivo analysis of the ubiquitin/proteasome system16. In addition, Liu et al. reported 
another transgenic mouse model with a reporter system of GFP modified by carboxyl fusion of a consensus 
ubiquitination signal sequence (CL1) isolated from yeast17. These reporter systems can monitor in vivo pro-
teasome activity, and also reflect the ubiquitination in living cells. Proteasomal degradation of most proteins 
depends on their ubiquitination, whereas the degron sequence of ornithine decarboxylase (ODC) is known to 
be directly recognized by the proteasome enzyme without ubiquitination18. Vlashi et al. and our group previ-
ously evaluated the ubiquitin-independent proteasome activity in living cells using ZsGreen-degronODC (Gdeg) 
reporter19–21. Gdeg reporter system consists of the green fluorescent protein ZsGreen fused to the degron of ODC, 
whose accumulation can be reflected by the ubiquitin-independent proteasome activity. Though Gdeg reporter 
has also been applied to in vivo studies such as tumor xenograft models22, a transgenic mouse model with this 
ZsGreen-degronODC reporter system has not been reported to date.
In the present study, we developed a transgenic mouse model with this reporter system, which enabled us 
to monitor the proteasome activity. Using this mouse model, we revealed constitutive elevation of proteasome 
activity during PanIN formation. Additionally, proteasome inhibition markedly reduced PanIN formation with 
decreased expressions of pERK and its downstream factors including cyclin D1, nuclear factor-kappa B (NF-κ B), 
and Cox2. Our data show crucial roles of proteasome activity in the initiation of PanIN.
Results
Generation of Gdeg transgenic mice. In order to monitor the proteasome activity, transgenic mice with 
the Gdeg reporter were constructed (referred to as Gdeg mice). The transgene consisted of the Gdeg reporter 
ligated between the cytomegalovirus (CMV) promoter and the simian virus 40 (SV40) poly-adenylation site 
(Fig. 1a). We first performed primary cell culture to confirm the expression of the transgene. Primary cultured 
fibroblasts exhibited no accumulation of Gdeg under normal conditions, but all of them responded to treat-
ment with the proteasome inhibitors MG132 and bortezomib and showed pronounced accumulation of Gdeg 
Figure 1. Generation of Gdeg transgenic mice. (a) Structure of the Gdeg transgene. (b) H&E staining, 
fluorescence imaging, and immunofluorescence staining for amylase and cytokeratin19 (CK19) of the pancreas 
of Gdeg mice. Asterisks indicate islet cells. Bar, 100 μ m.
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(Supplementary Fig. S1). This observation indicates constitutive expression of the transgene in Gdeg mice. 
Histologically, abundant accumulation of Gdeg was observed in the pancreas (Fig. 1b). Immunohistochemical 
analysis revealed that the majority of amylase positive acinar cells exhibited accumulation of Gdeg, whereas no 
accumulation of Gdeg was found in ductal cells expressing cytokeratin 19 (CK19) or islet cells (Fig. 1b). Expression 
of Gdeg mRNA in other cell types showing no Gdeg accumulation was confirmed by RT-PCR analysis using laser 
capture microdissection (LCM) and fluorescence-activated cell sorting (FACS) assays (Supplementary Fig. S2). 
These findings suggest that proteasome activity is relatively low in normal pancreatic acini. No pathological find-
ings due to gene transfection were observed in the pancreas or other tissues.
Transient elevation of proteasome activity following caerulein stimulation. Previous studies 
have shown that caerulein stimulation accelerates KrasG12D-mediated PanIN formation8. To evaluate the effect 
of caerulein stimulation on proteasome activity, Gdeg mice were administered with caerulein and the change 
of proteasome activity was analyzed. As previously reported, caerulein induced transient pancreatic inflam-
mation and ADM, which were replaced by normal acini within 2 weeks. Gdeg accumulation in acinar cells 
transiently decreased after caerulein administration (day1), but recovered within 2 weeks (Fig. 2a). This tran-
sient Gdeg reduction was improved by proteasome inhibitor MG132 without affecting the pancreatic damage 
(Supplementary Fig. S3), indicating potentially transient elevation of proteasome activity in the pancreas after 
caerulein stimulation. As shown in Fig. 2b, the Gdeg-positive rate in acinar cells was significantly decreased 
in mice at day1, compared to the control and mice at day14 after caerulein administration (P = 0.00004 and 
P = 0.0028, respectively).
Constitutive elevation of proteasome activity in KrasG12D-mediated PanIN formation. To mon-
itor proteasome activity during PanIN formation, our Gdeg mice were crossed to the well-established Pdx-1-Cre; 
LSL-KrasG12D model5 to generate Gdeg;Pdx-1-Cre;LSL-KrasG12D triple transgenic mice. The morphology of the 
pancreatic tissues of Gdeg;Pdx-1-Cre;LSL-KrasG12D mice was almost normal and formation of Alcian blue-positive 
PanINs was rare (Fig. 3a, upper and middle left). These results are consistent with previous observations in Pdx-
1-Cre;LSL-KrasG12D model. Intense accumulation of Gdeg was observed in pancreatic acini, which was similar to 
normal pancreatic tissue in Gdeg mice. In contrast, accumulation of Gdeg completely vanished in PanIN lesions 
(Fig. 3a, lower left). Though PanIN lesions spontaneously develop in Pdx-1-Cre;LSL-KrasG12D model, it takes 
long time to form high grade PanINs and the proportion of high grade PanIN lesions is limited in the pancreatic 
tissues5. For sufficient PanIN formation, additional factors such as caerulein stimulation are required in this 
model8. Thus, we next administered caerulein to triple transgenic mice. As expected, caerulein treatment mark-
edly accelerated PanIN formation. At 28 days after caerulein treatment, the pancreatic tissues contained massive 
PanINs and its precursor lesions (Fig. 3a, upper and middle right). The Alcian blue positive area of the pan-
creas was significantly increased in mice with caerulein treatment compared to mice without caerulein treatment 
(6.72 ± 0.98% vs 0.96% ± 1.13%, respectively, P = 0.00008) (Fig. 3b). Similar to those observed in mice without 
caerulein stimulation, PanINs exhibited elevated proteasome activity with no Gdeg accumulation. Expression of 
Gdeg mRNA was confirmed by LCM/RT-PCR in the PanIN cells showing no Gdeg accumulation (Supplementary 
Fig. S4).
Suppression of KrasG12D-mediated PanIN formation under proteasome inhibition. To address 
the significance of proteasome activity in the initiation of PanIN, we administered caerulein to Gdeg;Pdx-
1-Cre;LSL-KrasG12D mice in the presence or absence of MG132. Without MG132 treatment, Alcian blue-positive 
PanIN lesions were identified at day 14, and expanded at day 28. Elevation of proteasome activity in the pan-
creatic tissues persisted both at day14 and 28. Proteasome inhibition with MG132 dramatically reduced PanIN 
formation and maintained Gdeg accumulation in caerulein-treated Gdeg;Pdx-1-Cre;LSL-KrasG12D mice both at 
day 14 and 28 (Fig. 4a). In contrast, there was no Gdeg accumulation in PanIN lesions even after MG132 treat-
ment. Immunofluorescence analysis showed that proteasome inhibition preserved dense amylase positive acinar 
cells and reduced aberrant lesions expressing ductal marker CK19 (Fig. 4a), indicating suppression of PanINs. To 
thoroughly compare the extent of PanIN formation, we quantified the Alcian blue positive area in each case. As 
shown in Fig. 4b, the Alcian blue positive area of the pancreas was significantly decreased in mice with MG132 
treatment compared to mice without MG132 treatment both at day 14 (0.65 ± 0.51% vs 3.52 ± 0.85%, respectively, 
P = 0.00007) and day 28 (1.90 ± 1.70% vs 6.49% ± 1.58%, respectively, P = 0.0013). These data underscore the 
requirement of proteasome activity for the initiation of PanIN.
Expression of Ras signaling-related proteins in PanIN lesions under proteasome inhibition. 
Ras regulates a variety of signaling cascades, among which the MAPK/ERK pathway is the most important23,24. 
In order to gain additional insight into the effects of proteasome inhibition during PanIN initiation, we examined 
the expression of pERK and its downstream factors, Cyclin D1 and NF-κ B, by immunofluorescence analysis 
on pancreatic tissues of caerulein-treated Gdeg;Pdx-1-Cre;LSL-KrasG12D mice with or without MG132 treat-
ment at day 14 and 28 (Fig. 5a). The corresponding Alcian blue staining was used as a positive PanIN marker 
in Supplementary Fig. S5. We also quantified the positive staining rates of each factors in PanIN cells at day 28 
(Fig. 5b). The MAPK/ERK pathway was active in PanIN lesions, as determined by strong nuclear and cytoplasmic 
pERK staining. The positive staining rate of pERK in PanIN cells was significantly decreased in mice with MG132 
treatment compared to mice without MG132 treatment (7.35 ± 0.70% vs 69.6% ± 5.1%, respectively, P = 0.00007). 
As for pERK downstream factors, strong expression of cyclin D1 was observed in the nuclei of PanINs and sur-
rounding precursor lesions. The positive staining rate of cyclin D1 was significantly decreased under proteasome 
inhibition (59.3% ± 1.9% with MG132 treatment vs 91.8% ± 2.3% without MG132 treatment, P = 0.0001). We 
also observed that proliferation marker Ki67 showed a similar staining pattern to cyclin D1, and Ki67-positive 
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Figure 2. Transient elevation of proteasome activity following caerulein stimulation. (a) H&E staining, 
Alcian blue staining, fluorescence imaging, and immunofluorescence staining for amylase and cytokeratin19 
(CK19) of the pancreas of caerulein-treated Gdeg mice (n = 4). Bar, 100 μ m. (b) The Gdeg-positive rate in acinar 
cells was quantified in each group. Values are shown as mean ± SD. The Gdeg-positive rates were 69.3% ± 3.1% 
in control mice, 32.5% ± 5.2% in mice at day 1, and 60.2% ± 1.0% in mice at day14, respectively.
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Figure 3. Visualization of proteasome activity in KrasG12D-mediated PanIN lesions. (a) H&E staining, 
Alcian blue staining, and fluorescence imaging of the pancreas of Gdeg;Pdx-1-Cre;LSL-KrasG12D mice with or 
without caerulein treatment. Mice were intraperitoneally injected with caerulein or PBS, and analyzed on day 28 
(n = 4). Dashed lines on the fluorescence images mark PanIN lesions. Bar, 100 μ m. (b) Quantification of Alcian 
blue positive areas in each group. Values are shown as mean ± SD.
www.nature.com/scientificreports/
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Figure 4. Suppression of KrasG12D -mediated PanIN formation under proteasome inhibition. (a) H&E 
staining, Alcian blue staining, fluorescence imaging, and immunofluorescence staining for amylase and 
cytokeratin19 (CK19) of the pancreas of caerulein-treated Gdeg;Pdx-1-Cre;LSL-KrasG12D mice with or without 
MG132 administration (n = 3). Dashed lines on the fluorescence images mark PanIN lesions. Bar, 100 μ m.  
(b) Quantification of Alcian blue positive areas in each group. Values are shown as mean ± SD.
www.nature.com/scientificreports/
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Figure 5. Expression of Ras signaling-related proteins in PanIN lesions under proteasome inhibition. 
(a) Immunofluorescence staining for pERK, cyclin D1, Ki67, NF-κ B, Cox2, Shh, Sox9, and β -catenin of the 
pancreas of caerulein-treated Gdeg;Pdx-1-Cre;LSL-KrasG12D mice with or without MG132 administration 
(n = 3). Dashed lines on the fluorescence images mark PanIN lesions. Bar, 100 μ m. (b) Quantification of the 
positive staining rates of pERK, cyclin D1, Ki67, NF-κ B, Cox2, Shh, Sox9, and β -catenin at day 28. Values are 
shown as mean ± SD.
www.nature.com/scientificreports/
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cells were decreased by MG132 treatment (7.1% ± 2.8% with MG132 treatment vs 19.8% ± 0.6% without MG132 
treatment, P = 0.0035). Nuclear and cytoplasmic staining of NF-κ B was evident in PanINs in mice without 
MG132 treatment, whereas the expression of NF-κ B was rarely seen in mice with MG132 treatment. The positive 
staining rate of NF-κ B was significantly different between two groups (14.8% ± 8.8% with MG132 treatment vs 
64.0% ± 2.1% without MG132 treatment, P = 0.0015). Cox2 is one of the target genes of NF-κ B, and is respon-
sible for the generation of several inflammatory mediators25. Similar to NF-κ B, abundant Cox2-positive cells 
were observed in PanIN lesions, and the positive staining rate of Cox2 in PanIN cells was significantly decreased 
under proteasome inhibition (67.3% ± 9.2% with MG132 treatment vs 97.6% ± 0.7% without MG132 treatment, 
P = 0.01). We also investigated other oncogenic factors such as Shh26, Sox927 and β -catenin28, but the positive 
staining rates of these factors were unaffected by proteasome inhibition (P = 0.66, 0.37, and 0.48, respectively).
The effect of proteasome inhibitor after PanIN formation. We further assessed whether proteasome 
inhibition with MG132 affected PanIN lesions that had already formed. After development of PanIN, MG132 
could not reduce PanIN lesions in the pancreas of Gdeg;Pdx-1-Cre;LSL-KrasG12D mice (Fig. 6a), with the Alcian 
blue positive area of 6.35 ± 2.07% at day 28 (Fig. 6b). Immunofluorescence analysis showed that MG132 could 
not decrease the expression of pERK and its downstream cyclin D1, NF-κ B, and Cox2 in the formed PanIN 
lesions accompanying increased proteasome activity (Fig. 6c). The positive staining rates of pERK, cyclin D1, 
NF-κ B, and Cox2 in PanIN cells were 72.6% ± 2.6%, 75.8% ± 3.0%, 62.7% ± 3.6%, and 88.2% ± 1.5%, respectively 
(Fig. 6d). No significant difference was observed in the control mice with vehicle injection instead of MG132 
(Supplementary Fig. 6). These observations indicated that proteasome activity might regulate the initiation of 
PanIN but not the maintenance of PanIN.
Discussion
The proteasome is involved in a diverse array of biological processes with various tissue and/or cell-specific sub-
types29,30. Cancer cells are largely dependent on the proteasome and proteasome activity is significantly activated 
in cancer cells with proliferating and hypermetabolic activities9,11. While the proteasome plays critical roles in 
advanced cancers including pancreatic cancer, its significance in the initiation of cancers are not disclosed. In 
the present study, we first established a transgenic mouse model with the Gdeg reporter. This Gdeg reporter 
system consists of ZsGreen fused to the degron motif18, whose accumulation indicates low proteasome activity. 
Expression of Gdeg mRNA in all examined pancreatic tissues was confirmed by RT-PCR analysis using LCM and 
FACS assays (Supplementary Fig. S2). The proteasome inhibitors induced the accumulation of Gdeg in primary 
cultured fibroblasts, indicating the transgene function in Gdeg mice (Supplementary Fig. S1).
ADM to PanIN sequence is the initial event of pancreatic carcinogenesis5,6. Though inflammatory insult to 
the pancreas transiently causes ADM, it is not sufficient to form PanIN and mutant KRAS is required for PanIN 
formation7,8. Understanding this process is critically important for developing early cancer detection methods 
and effective treatments. In combination with Pdx-1-Cre;LSL-KrasG12D model, we successfully monitored protea-
some activity in the initiation of PanIN. Our mouse model revealed that normal pancreatic acinar cells had low 
proteasome activity, whereas proteasome activity was definitely elevated in PanIN lesions. Caerulein stimulation 
induced briefly elevation of proteasome activity in pancreatic acinar cells and formation of ADM lesions, both of 
which were only transient in the absence of mutant KRAS. On the other hand, mutant KRAS caused constitutive 
elevation of proteasome activity and accelerated ADM to PanIN sequence, demonstrating the potential require-
ment of proteasome activity in Kras-induced PanIN formation (Fig. 7). The significance of proteasome activity 
was further verified by the proteasome inhibitor, which clearly reduced PanIN formation without affecting ADM 
events. It was noteworthy that the proteasome inhibitor had no effect on PanIN lesions that had already formed, 
indicating that ADM to PanIN sequence is irreversible and proteasome activity is especially required for the ini-
tiation of PanIN. Although Gdeg reduction was improved by proteasome inhibitor without affecting pancreatic 
damage (Supplementary Fig. 3), we cannot rule out the effects of factors other than proteasome activity such as 
stress-induced mRNA and lysosomal degradation on Gdeg reduction, and this is one of the limitations of our 
study.
To further understand the effects of proteasome inhibition, we focused on the RAS-induced oncogenic path-
ways. The RAS/MAPK/ERK pathway is activated in many cancers and participates in the regulation of a large 
variety of processes31,32. In our study, the RAS/MAPK/ERK pathway was active in PanIN lesions, as confirmed by 
strong immunostaining of pERK. In contrast, decreased levels of pERK were observed when proteasome activity 
was inhibited. ERK activity regulates the induction of cyclin D123. Overexpression of cyclin D1 shortens the G1-S 
transition and promotes cell progression and differentiation. The NF-κ B pathway is another important path-
way that is crucial in mediating inflammation-induced tumor growth and progression24,33. Cox2 is regulated by 
NF-κ B and promotes cell survival, proliferation, and angiogenesis and inhibit apoptosis25. All of these factors 
were activated in PanIN lesions, and were reduced by proteasome inhibition in this study. Although these data 
cannot exclude the consequence of PanIN reduction after proteasome inhibition, it may be possible that protea-
some activity is involved in pERK levels and its downstream pathways associated with cell cycle and inflamma-
tion. A limitation of our study is the lack of molecular evidence, and the mechanistic insights into the effect of 
proteasome inhibitors including MG132 and other compounds such as borezomib should be further investigated.
In summary, elevation of proteasome activity plays a critical role in the initiation of PanIN. Proteasome activ-
ity is worthy of further study as a key component of pancreatic carcinogenesis.
Methods
Transgenic mouse lines. The degron sequence of the ornithine decarboxylase (ODC) is known to be 
directly recognized by proteasomes18, which leads to the immediate destruction of the involved protein. The 
ZsGreen-degronODC (Gdeg) reporter expresses the green fluorescent protein ZsGreen fused to the degron of 
www.nature.com/scientificreports/
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ODC, which intracellularly accumulates as a result of the low activity of the 26S proteasome. We constructed 
a 2.7-kb transgene including the Gdeg reporter combined with the cytomegalovirus (CMV) promoter and the 
simian virus 40 (SV40) poly-adenylation site (Fig. 1a). The purified transgene was microinjected into ferti-
lized oocytes derived from ICR mice at the single-cell stage. The transgene was identified by polymerase chain 
Figure 6. The effect of proteasome inhibitor after PanIN formation. Gdeg;Pdx-1-Cre;LSL-KrasG12D mice were 
simultaneously treated with two sets of caerulein and MG132 on alternating days (left panels), or first treated 
with two sets of caerulein and after PanIN formation further treated with two sets of MG132 on day 14 and 
16 (right panels). Mice were analyzed on day 28 (n = 3). (a) H&E staining, Alcian blue staining, fluorescent 
imaging of the pancreas of Gdeg;Pdx-1-Cre;LSL-KrasG12D mice. (b) Quantification of Alcian blue positive areas at 
day 28. Values are shown as mean ± SD. (c) Immunofluorescence staining for pERK, cyclin D1, NF-κ B and cox2 
of the pancreas of Gdeg;Pdx-1-Cre;LSL-KrasG12D mice. Dashed lines on the fluorescence images mark PanIN 
lesions. Bar, 100 μ m. (d) Quantification of the positive staining rates of pERK, cyclin D1, NF-κ B, and Cox2 in 
PanIN cells at day 28. Values are shown as mean ± SD.
www.nature.com/scientificreports/
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reaction (PCR) analysis following amplification of a unique 1.6-kb fragment using the following primers spe-
cific for the CMV promoter: 5′ -GTCATTAGTTCATAGCCCATATATGGAGTT-3′ and the SV40 sequencesx: 
5′ -GCAGTGAAAAAAATGCTTTATTTG-3′ .
Gdeg transgenic mice were further crossed with Pdx-1-Cre; LSL-KrasG12D mice5 (provided by Dr. David 
Tuvenson, Cold Spring Harbor Laboratory, Long Island, NY) to create Gdeg; Pdx-1-Cre; LSL-KrasG12D triple trans-
genic mice.
Caerulein and MG132 treatment. For caerulein treatment, 8-week old Gdeg mice or Gdeg; Pdx-1-Cre; 
LSL-KrasG12D mice were intraperitoneally injected with caerulein (50 μ g/kg; Sigma-Aldrich) or PBS on 2 alternat-
ing days once every hour for 6 hours each day7. The final day of caerulein injection was considered day 0.
For MG132 treatment, MG132 (Calbiochem, San Diego, CA) was dissolved in dimethyl sulfoxide (DMSO) 
and intraperitoneally administered. At 8 weeks of age, Gdeg mice or Gdeg; Pdx-1-Cre; LSL-KrasG12D mice were 
administered with MG132 at a dose of 5 mg/kg dissolved in 50 μ l of DMSO or with vehicle alone together with 6 
hourly injections of caerulein (50 μ g/kg). The series of MG132 and caerulein injections were repeated on alternat-
ing days. After two sets of MG132 and caerulein injections, mice were analyzed on day 14 or 28.
For MG132 treatment after PanIN formation, 8-week old Gdeg; Pdx-1-Cre; LSL-KrasG12D mice were first 
treated with 6 hourly injections of caerulein (50 μ g/kg) on two alternating days. Mice were further treated with 
MG132 at a dose of 5 mg/kg dissolved in 50 μ l DMSO on day 14 and 16, and analyzed on day 28.
Protocols were approved by the Animal Care Committee of Tokyo Medical and Dental University (Permission 
No. 0150044), and all mouse experiments were carried out in accordance with the approved guidelines.
Immunofluorescence and immunohistochemistry. Pancreatic tissues were fixed overnight in 4% para-
formaldehyde as previously described16, embedded in paraffin, and sectioned (3.5 μ m in thickness). Hematoxylin 
and eosin (H&E) staining and Alcian blue staining were performed. For immunofluorescence, tissue sections 
were prepared according to standard procedures. After deparaffinization and antigen retrieval in 10 mM sodium 
citrate buffer pH 6.0, slides were incubated in permeabilization buffer (0.1% Triton X-PBS) for 30 minutes, fol-
lowed by incubation in blocking buffer (3% bovine serum albumin-PBS) for 30 minutes and subsequent exposure 
to the primary antibodies overnight at 4 °C. The primary antibodies used in this study are listed in supplementary 
table 1. The sections were then treated for 1 hour with the secondary antibody and Hoechst 33342 solution for 
nuclear staining. Alexa Fluor 568 donkey anti-rabbit, Alexa Fluor 647 goat anti-rabbit, Alexa Fluor 647 goat 
anti-mouse, and Alexa Fluor 647 chicken anti-goat antibodies (Molecular Probes; Invitrogen) were used as the 
secondary antibodies at a dilution of 1:500. After mounting, the slides were visualized with a fluorescence micro-
scope (Carl Zeiss, Oberkochen, Germany).
Evaluation of Alcian blue positive areas. To quantify relative Alcian blue positive area, six random, 
non-overlapping images were obtained at a magnification of x200. For each image, the Alcian blue positive area 
and the total pancreatic epithelial area were measured using cellSens Dimension software version 1.6 (Olympus, 
Tokyo, Japan), and the percentage of the Alcian blue positive area was calculated.
Statistical analysis. Data are presented as mean ± standard deviation (SD). P-values were acquired with 
the Student’s t test using SPSS version 21.0 (SPSS, Chicago, IL). P < 0.05 was considered statistically significant.
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